Audio Journal of Oncology Podcast

By Audio Medica News

Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.


Category: Science

Open in Apple Podcasts


Open RSS feed


Open Website


Rate for this podcast

Subscribers: 6
Reviews: 0
Episodes: 149

Description

As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoken comments on the clinical implications of cancer developments in the real-world context, as practiced by cancer doctors and clinicians around the globe. The AJO Podcast originates from the Audio Journal of Oncology staffed by ex-BBC professional journalists, and mentored by world-leading cancer practitioners from bodies including the American Society of Clinical Oncology, Cancer Research UK, Istituto Nazionale dei Tumori, and Action Radiotherapy. Each podcast is produced to the highest standards of audio recording and journalism and is subject to editorial appraisal to maintain that content, balance and clinical relevance of news and comment are delivered in a manner that's easy and enjoyable for listening while travelling, taking exercise, working or just relaxing. Please contact Audio Medica with your comments and make your contribution to supporting a vibrant community of clinical cancer communicators!

Episode Date
Jiujie Cui MD PhD, CSCO 2026: Early Findings Show KRAS-G12D Inhibitor More than Doubles Median Overall Survival in Patients with Advanced Pancreatic Cancer
Sep 24, 2026
Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries
Sep 08, 2026
John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy
Aug 31, 2026
David R Spigel MD; ASCO 2026: EGFR Exon-20 Insertion Directed Initial Therapy Cuts Disease Progression in Patients with Advanced Non-Small Cell Lung Cancer
Aug 25, 2026
Robert C. Stein, PhD FRCP; ASCO 2026: Gene Test Finds Most Patients with High Risk ER-positive, HER2-negative Early Breast Cancer Do Not Benefit from Chemotherapy
Aug 17, 2026
Bjørn Henning Grønberg MD PhD; ASCO 2026: Adding Thoracic Radiotherapy Did Not Prolong Lives of Patients with Extensive Stage Small Cell Lung Cancer Being Treated with Chemo-Immunotherapy. COMMENT: David R Spigel MD
Jul 22, 2026
Kevin Kalinsky MD; ASCO 2026: ASCENT-04 Study Finds Sacituzumab Govitecan plus Pembrolizumab Helps Patients with Previously Untreated Metastatic PD-L1 Positive Triple Negative Breast Cancer Live Longer Without Progression Beyond Subsequent Therapies
Jul 14, 2026
Wing-Lok Chan MBBS; 2026 ASCO: Patients with Advanced Cancer Using The SUPPORT+ Mobile Phone App With Nurse Supervision have Better Quality of Life and Fewer Hospitalizations
Jul 08, 2026
Ghassan K. Abou-Alfa MD PhD; ASCO 2026: Adding Doublet Immune Checkpoint Inhibition to Embolization with or without anti-Growth Factor TKI Therapy Extends Progression Free Survival in Patients with Hepatocellular Cancer
Jun 30, 2026
Jonathan W. Goldman MD and David R Spigel MD; ASCO 2026: Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results
Jun 23, 2026
Mark A Dickson, ASCO 2026: Abemaciclib Brings Marked Increase in Progression Free Survival for Patients with Advanced Dedifferentiated Liposarcoma
Jun 15, 2026
Jana de Boniface MD PhD; ASCO 2026: Omitting Axillary Lymph Node Dissection is Safe for Patients with Breast Cancer Macrometastases to One or Two Sentinel Lymph Nodes
Jun 11, 2026
Jean-Marc Classe, MD PhD; ASCO 2026: Timing of Surgery for Advanced Ovarian Cancer among Neoadjuvant and Adjuvant Chemotherapy Cycles: Early Findings from Randomized CHRONO Trial
Jun 09, 2026
Peter Schmid MD PhD; ASCO 2026: Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer
Jun 05, 2026
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Jun 04, 2026
Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study
Jun 02, 2026
Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma
May 21, 2026
Ahmad A Tarhini MD PhD, AACR 2026: Molecular Glue Brings New Hope for Patients with BRAF or NRAS-Mutant Melanoma or Other RAS/RAF-driven Malignancies
May 19, 2026
Shuguang Leng MBBS PhD, 2026 AACR: Wildfire Smoke Pollution Associated with Increased Lung, Colorectal, Breast, Bladder and Hematopoietic Cancer Rates
May 15, 2026
Rukhmini Bandyopadhyay MD, AACR 2026: AI “Pathomics Platform” Selects Immunotherapy, Predicts Outcome for Patients with Metastatic Non-Small Cell Lung Cancer
May 13, 2026
Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer
May 06, 2026
Marija Balic MD PhD, AACR 2026: Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer
Apr 30, 2026
Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity
Apr 28, 2026
Moran Amit MD PhD; AACR 2026: Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life
Apr 27, 2026
Byoung Chul Cho MD PhD; AACR 2026: New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy
Apr 24, 2026
Elena Garralda MD PhD, AACR 2026: Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors
Apr 23, 2026
Icro Meattini MD; 2026 EBCC: Safe to Avoid Endocrine Therapy in Older Women with Low Risk Breast Cancers: EUROPA Study Interim Findings
Apr 16, 2026
Amparo Garcia-Tejedor MD, PhD; 2026 EBCC: Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema
Apr 13, 2026
Eline Verreck BSc; 2026 EBCC: Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer
Apr 06, 2026
Fleur Mauritz MD; EBCC 2026: RAPCHEM Study Shows Risk-Based Radiotherapy De-Escalation is Safe After Primary Systemic Therapy for Early Breast Cancer
Apr 03, 2026
Jelle Wesseling MD PhD; 2026 EBCC: ‘Lord’ Trial Finds Active Surveillance for Estrogen-Receptor-Positive, HER2- Negative, Grade 1–2 DCIS Just As Effective as Standard Therapy
Apr 02, 2026
Elisa Agostinetto MD; 2026 EBCC: Circulating Tumor DNA Trumps Clinical Prognostic Markers After Neoadjuvant Therapy for Patients with Early Breast Cancer
Apr 01, 2026
Kerstin Wimmer MD; 2026 EBCC: Polyurethane-Coated Implants Reduce Capsular Contracture Risk after Mastectomy with Radiotherapy for Breast Cancer
Mar 31, 2026
Fatima Cardoso MD; 2026 EBCC: OASIS-4 Trial Finds Elinzanetant Cuts Vasomotor Symptoms (“Hot Flashes”) in Endocrine Therapy-Treated Patients with Breast Cancer
Mar 30, 2026
Elisabetta Bonzano MD PhD; 2025 EBCC: BRAVE-HEART Study Shows How Breath-Holding System Halves Coronary Radiation Dose During Left Breast Irradiation
Mar 27, 2026
Philip Poortmans MD PhD; 2026 EBCC: European Breast Cancer Conference: Focus on Therapy De-escalation and Individualization
Mar 27, 2026
Tess Snellen MD; 2026 EBCC: Molecular Test Distinguishes Ipsilateral Second Primary from Recurrent Breast Cancer
Mar 25, 2026
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Mar 20, 2026
Hope S. Rugo, MD; SABCS 2025: Selective Estrogen Degrader Giredestrant Brings Clinically Meaningful Improvements in Metastatic Breast Cancer: evERA Breast Cancer Trial
Mar 06, 2026
Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia
Mar 02, 2026
Juan Du MD PhD,  ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma
Feb 23, 2026
Thorsten Kühn MD PhD; SABCS 2025: No Need for Axillary Node Dissection When Clinically Node-Positive Breast Cancers Convert to Node-Negative After Neoadjuvant Chemotherapy
Feb 19, 2026
María-Victoria  Mateos; ASH 2025: Unprecedented Survival Benefits with BCMA/CD3 Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma: Majestec-3 Study Findings
Feb 13, 2026
Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial
Feb 10, 2026
Wojciech Jurczak MD PhD; ASH 2025: Big Study Suggests Non-Covalent BTK Inhibitor Pirtobrutinib Could be New Standard-of-Care for Patients with Untreated Chronic Lymphocytic Leukemia
Feb 05, 2026
Gaorav Gupta MD PhD; SABCS 2025: Pre-Op Radiation Improved T-cell Infiltration in Hormone Receptor-positive, HER2-negative Invasive Breast Cancer; Could Boost Systemic Therapy Responses
Feb 03, 2026
Lorenzo Falchi MD; ASH 2025: Bispecific Antibody Epcoritamab Combination Beats Standard of Care for Patients with Relapsed/Refractory Follicular Lymphoma
Jan 30, 2026
Christian F. Singer MD; 2025 SABCS: Denosumab Bone Protection in ER-Positive Early Breast Cancer Brings Added Benefit with Progesterone Receptor Positive Tumors: ABCSG 18 Study Findings
Jan 29, 2026
Amir Fathi MD; ASH 2025: Paradigm Study Finds Young, Fit Adults with Acute Myeloid Leukemia Do Better with Gentler Azacitidine/Venetoclax Initial Therapy
Jan 28, 2026
Jennifer A. Woyach MD, ASH 2024: The Non-Covalent Bruton’s Tyrosine Kinase-Inhibitor Pirtobrutinib is As Effective, While Less Toxic, In Relapsed/Refractory Chronic Lymphocytic Leukemia
Jan 24, 2026
Alexis Ann LeVee MD; 2025 SABCS: Pre-Operative Gut Microbiome Predicts Complete Response to Immune Checkpoint Inhibition in Patients with Early-stage HER2-positive Breast Cancer
Jan 22, 2026
Meletios Dimopoulos; ASH 2025: B-Cell Maturation Antigen Bispecific Antibody Linvoseltamab Brings High Response Rates in Patients with Relapsed/Refractory Multiple Myeloma
Jan 20, 2026
Antonio Jimenez Jimenez MD MS; ASH 2025: Donor Choice No Longer a Barrier to Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies
Jan 19, 2026
Safna Naozer Virji MBBS FPBS; 2025 SABCS: Oncoplastic Breast Cancer Surgery Study Reports High Efficacy with Superior Psychosocial Outcomes in a Low or Middle Income Country Setting
Jan 16, 2026
Luciano Costa, MD PhD; ASH 2025:  CAR T Cell Brings Profound Benefit with Long-Term Progression-Free Survival in Patients with Standard-Risk Relapsed/Refractory Multiple Myeloma
Jan 14, 2026
Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in Patients with ER-Positive, HER2-Positive Early Breast Cancer  
Jan 09, 2026
Jesse Tettero MD PhD; ASH 2025: Measurable Residual Disease Can Predict Overall Survival in Patients with Acute Myeloid Leukemia
Jan 08, 2026
Hisham Abdel-Azim MD MS; ASH 2025: Next Generation Sequencing-Assessed Minimum Residual Disease Identifies Young Patients with High-risk/Relapsed B-cell Acute Lymphoblastic Lymphomas Who Can Omit Pre-Transplant Total Body Irradiation
Jan 06, 2026
Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
Dec 18, 2025
Daniel J Zheng MD, MHS, MSHP; ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke! “Financial Toxicity” is Often More Worrying than your Child’s Cancer
Dec 16, 2025
Peihua Lu MD and Robert Chiesa MD PhD; ASH 2025, Orlando: Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies
Dec 12, 2025
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
Dec 01, 2025
Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer
Nov 24, 2025
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Nov 19, 2025
Erwei Song MD PhD, ESMO Berlin: Antibody Drug Conjugate Trastuzumab Resetecan Brings Early Significant Progression Free Survival Benefit in Patients with Previously Treated HER2+ Advanced Breast Cancer
Nov 14, 2025
Andrew Clamp MD, PhD, ESMO Berlin: Weekly Dose-Dose Chemotherapy Brings Big Survival Benefit for Patients with High-Risk Ovarian Cancer
Nov 12, 2025
Nima Nabavizadeh MD; ESMO Berlin: Multi-Cancer Early Detection Test: PATHFINDER II study Finds Early Promise
Nov 07, 2025
Xiuning Le MD PhD; ESMO 2025: Sevabertinib Success for Patients with HER2-Mutated Non-Small Cell Lung Cancer in SOHO-01 Study
Oct 31, 2025
ESMO 2025; Christof Vulsteke MD PhD: Perioperative Enfortumab Vedotin Therapy With Pembrolizumab Boosts Event-Free and Overall Survival in Platinum-Ineligible Patients with Muscle-Invasive Bladder Cancer: KEYNOTE-905 study
Oct 30, 2025
Xichun Hu MD PhD; ESMO 2025: Antibody Drug Conjugate Trastuzumab Botidotin Outperforms Trastuzumab Emtansine in Patients with HER2-Positive Unresectable or Metastatic Breast Cancer
Oct 28, 2025
Martin Wermke MD; ESMO 2025: Initial Therapy with Bi-Specific T-cell Engager Tarlatamab Promises Better Outcomes in Patients with Small Cell Lung Cancer
Oct 27, 2025
John P. Crown MD MBA: ESMO 2025, Berlin: Adjuvant Ribociclib Brought Longer Freedom from Metastases for Patients with HR+/HER2- Early Breast Cancer: NATALEE Five Year Outcomes
Oct 24, 2025
Javier C Cortés MD PhD: ESMO 2025, Berlin: Initial Therapy with Sacituzumab Govitecan Improves Progression-Free Survival in Patients with Newly-Diagnosed Metastatic Triple Negative Breast Cancer—ASCENT-03 study
Oct 23, 2025
Trevor Leong  MD: Operable Gastric or GE-Junction Adenocarcinoma: No Advantage from Neoadjuvant Radiotherapy
Oct 13, 2025
Domenica Lorusso MD PhD: Adding Early PD-1 Checkpoint Inhibition brings Big Reduction of Deaths for Patients with Newly Diagnosed Locally Advanced High-Risk Cervix Cancer
Oct 06, 2025
James Larkin FRCP, PhD: CheckMate 067 Study 10-Year Data Show Advanced Melanoma Landscape Transformed by Combo Checkpoint Inhibitor Therapy
Oct 03, 2025
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
Oct 01, 2025
Rebecca Dent MD: ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……
Sep 30, 2025
Bart Neyns MD PhD: Patients with Recurrent Glioblastoma Lived Markedly Longer in Phase 1 Study of Intracranial Autologous Myeloid Dendritic Cell Therapy
Sep 26, 2025
Victor Velculescu MD PhD: Ovarian Cancer Noninvasive Detection by Circulating DNA Fragmentome and Protein Biomarker AI Analysis
Sep 24, 2025
Timothy Yap MD PhD MBBS: Selective PARP1 Inhibitor Saruparib Clinical Promise in Solid Tumors with Homologous Recombination Repair Deficiency
Sep 22, 2025
Stacey Kenfield ScD and June Chan ScD: Prostate Cancer Management: New Evidence of Big Benefit from Exercise:
Sep 19, 2025
Jonathan T. Yang MD PhD: Radiosensitizer Shows Early Clinical Promise to Support Glioblastoma Radiotherapy
Sep 18, 2025
Heather McArthur MD MPH: Adjuvant Checkpoint Inhibition: Did Not Improve Survival in Patients with Triple-Negative Breast Cancer
Sep 17, 2025
Stefan Paepke MD: An End to “Jumping Breasts” with Mesh Supported Pre-Pectoral Breast Implants
Sep 16, 2025
Sophie Bosma MD PhD:“Young Boost” Trial Finds Low-Dose Radiation Boost Optimal for Young Patients with High-Risk Early Breast Cancer
Sep 15, 2025
Adri Voogd PhD: Ductal Carcinoma in Situ: Good Outcomes from Breast Conserving Therapy, but Benefits, Risks, Costs Still Need to be Optimized
Sep 12, 2025
Annemiek van Hemert MD PhD: “Breast Cancer: MARI Node Marker Helps Most Patients with Extensive Nodal Disease Safely Avoid Axillary Lymph Node Dissection”
Sep 11, 2025
Tim Rattay MBChB PhD: Artificial Intelligence Tool Minimizes Arm Lymphedema After Breast Cancer Surgery and Radiotherapy
Sep 10, 2025
Yasmin Civil MD PhD: Low-Risk ER+ Breast Cancer: ABLATIVE Trial Finds Marked Benefit from MRI-Guided Single-Dose Neoadjuvant Partial Breast Radiotherapy
Sep 08, 2025
Neo-Adjuvant Pembrolizumab Improved Outcomes with High-Risk ER+ HER2- Early Breast Cancer
Sep 02, 2025
Laura J. van 't Veer, PhD
Aug 28, 2025
Érica A. Oliveira PhD: How to Overcome Drug Resistance: Patient Derived Organoids Study Finds Epigenetic Pathways in Colorectal Cancer
Aug 22, 2025
Christian Singer MD: Neoadjuvant Olaparib Combination Beats Standard of Care in Patients with Homologous Recombination Deficient BRCA 1/2-Positive Triple-Negative Breast Cancer
Aug 05, 2025
Erica L. Mayer MD MPH: Adjuvant Abemaciclib: Start Low, then Dose Escalate in Early-stage HR+/HER2- Breast Cancer: TRADE Study Findings
Jul 18, 2025
Patients with Early-Stage Non-Squamous Non-Small Cell Lung Cancer Who can Benefit from Adjuvant Chemotherapy
Jul 12, 2025
Adjuvant Nivolumab Extends Disease-Free Survival in Patients with High-Risk Head and Neck Cancers
Jul 03, 2025
Luis G Paz-Ares MD PhD
Jun 30, 2025
Elena Elez, Barcelona, ASCO: BRAF Inhibitor Encorafenib Delays Progression, Extends Survival in Patients with Inoperable BRAF V600E Mutant Colorectal Cancer
Jun 19, 2025